Johnson & Johnson Won UK Approval for Its Psoriasis Pill. Here's Where the Stock Could Go by 2030

Johnson & Johnson shares reacted to two drug catalysts within days as the UK approved Icotyde, its once-daily oral pill for psoriasis, and new ERLEADA (apalutamide) prostate cancer data arrived at the ESMO Congress in Madrid on Oct. 24. J&J closed at $263.81 on Oct. 23, up 27.5% in 2026. The article says Icotyde’s approval came from Britain’s medicines regulator on Oct. 23, while ERLEADA data showed a 62% reduction in risk of recurrence or death with ERLEADA plus hormone therapy versus surgery alone in high-risk patients; an open-label substudy randomized 408 participants. It also notes the role of dilution in 2027 guidance and a valuation around 24 times forward earnings.